• Protocols

• EAY191N4

  OPEN TO ACCRUAL

  Ph2 Randomized Selumetinib, Olaparib or Selumetinib in Patients w/Ovarian and Endometrial Cancer
  
  

• UW23105

  OPEN TO ACCRUAL

  Ph 1/2 Study of DCC-3116 w/ RAS/MAPK Pathway Inhibitors in Pts w/ Solid Tumors w/ RAS/MAPK Mutations